HALLE/SAALE, Germany, 05 April 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), has the honour to […]
Favourable results enable longer patient treatment HALLE/SAALE, Germany, 04 April 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat […]
HALLE/SAALE, Germany, 31 March 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is […]
Expands Management Board with Senior Hire HALLE/SAALE, Germany, 23 March 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat […]
Phase 2a study of novel treatment for Alzheimer’s disease initiated Phase 1 PQ912 data, a first in class Glutaminyl Cyclase (QC) inhibitor for the treatment of […]
The Symposium will be held from 9 to12 March 2016 at the Athens Hilton in Athens, Greece HALLE/SAALE, Germany, 09 March 2016 – Probiodrug AG (Euronext […]
HALLE/SAALE, Germany, 7 March 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its Full Year […]
HALLE/SAALE, Germany, 22 February 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is […]
HALLE/SAALE, Germany, 28 January 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that Dr Konrad Glund, […]